Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tiziana Life Sciences Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
TLSA
Nasdaq
2836
www.tizianalifesciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tiziana Life Sciences Ltd
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
- Aug 6th, 2026 5:00 am
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
- Jul 31st, 2026 6:55 am
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
- Jul 31st, 2026 5:00 am
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
- Jul 22nd, 2026 5:00 am
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
- Jun 25th, 2026 7:05 am
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
- Jun 25th, 2026 5:00 am
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
- May 29th, 2026 4:55 pm
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
- May 28th, 2026 5:00 am
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
- May 22nd, 2026 2:48 pm
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
- May 21st, 2026 9:44 am
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
- May 21st, 2026 9:00 am
Sector Update: Healthcare Stocks Gain Late Afternoon
- May 19th, 2026 1:55 pm
Tiziana Life Sciences price target boosted on foralumab update
- May 19th, 2026 1:12 pm
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
- May 19th, 2026 7:42 am
Scroll